Durham.

Position:Triangle
 
FREE EXCERPT

DURHAM--Drug developer Tranzyme netted about $48 million in its initial public offering of stock, despite having to cut the price of its shares. It originally sought to sell 5 million at $11 to $13 each, but...

To continue reading

FREE SIGN UP